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ARTICLE

A Network Pharmacology Approach for the Identification
of Common Mechanisms of Drug-Induced Peripheral
Neuropathy
Guillermo de Anda-Jáuregui1,2, Brett A. McGregor1, Kai Guo1 and Junguk Hur1,*

Drug-induced peripheral neuropathy is a side effect of a variety of therapeutic agents that can affect therapeutic adherence
and lead to regimen modifications, impacting patient quality of life. The molecular mechanisms involved in the development
of this condition have yet to be completely described in the literature. We used a computational network pharmacology approach to explore the Connectivity Map, a large collection of transcriptional profiles from drug perturbation experiments to
identify common genes affected by peripheral neuropathy-inducing drugs. Consensus profiles for 98 of these drugs were
used to construct a drug–gene perturbation network. We identified 27 genes significantly associated with neuropathy-
inducing drugs. These genes may have a potential role in the action of neuropathy-inducing drugs. Our results suggest that
molecular mechanisms, including alterations in mitochondrial function, microtubule and cytoskeleton function, ion channels, transcriptional regulation including epigenetic mechanisms, signal transduction, and wound healing, may play a critical
role in drug-induced peripheral neuropathy.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
✔ Drug-induced peripheral neuropathy (DIPN) is a side
effect of many drugs that detrimentally impacts the quality
of life of patients and therapeutic adherence. Mechanisms
through which drugs can induce neuropathy have been
described for a limited number of drugs.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔ This study presents a computational approach based
on graph theory to explore gene perturbation profiles of
neuropathy-inducing drugs and to identify genes with potential functional implications in the development of DIPN.

Drug-
induced peripheral neuropathy (DIPN), also known as
medication-induced or iatrogenic neuropathies, involves damage to the peripheral nervous system as an adverse effect of
a therapeutic (or diagnostic) agent.1–3 DIPN comprises a small
subset of neuropathies, accounting for only 2–4% of all neuropathy cases.4,5 Although this incidence rate may seem small,
the condition impacts the patient’s quality of life and influences
therapeutic adherence.6 Several drug classes have peripheral
neuropathy as a side effect. Typical examples include chemotherapeutics,7 antibiotics,8 and HIV treatments.9
Currently, it is understood that drugs may induce peripheral neuropathy through different types of damage at the
cellular level. These include (i) axonal degeneration through

WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔ We used a network model to integrate high-throughput
drug perturbation profiles to identify genes that are commonly affected by neuropathy-inducing drugs. With this
model, we explored and identified genes associated with
biological functions whose perturbation may be linked to
DIPN.
HOW MIGHT THIS CHANGE DRUG DISCOVERY,
DEVELOPMENT, AND/OR THERAPEUTICS?
✔ Our network-
based model provides a novel way of
generating hypotheses that may drive new experimental
efforts to identify mechanisms behind DIPN.

a dying-back mechanism, (ii) segmental demyelination, and
(iii) damage to the soma of the neuron.1,10 However, the molecular entities that can lead to these perturbations are varied. Furthermore, the full spectrum of neuropathy-inducing
drugs (NIDs) has not been associated with mechanisms that
can explain their link to this condition and an understanding
of the molecular entities involved in the development of this
adverse reaction is still needed.
The rise of genomic technologies has generated large
amounts of biologically relevant data that require novel
computational approaches for their analysis.11 This study
of disease from a systems biology perspective has allowed
the development of descriptive models that link molecular
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alterations to physiological and pathological conditions,
leading to new insights. The Connectivity Map (CMap) project,12,13 which has generated a large collection of transcriptional responses to drug perturbation in cultured human
cell lines, is a useful resource for the development of such
models.
The use of network theory provides a theoretical framework suitable for the exploration of drug effects at different
biological levels14,15 and for the integration of large-scale
drug information.16 The CMap data have been studied
through the construction of network models by others.17,18
In this work, we systematically identified potential molecular
mechanisms that may be implicated in DIPN. We developed
a network-based approach to connect peripheral NIDs to
targets at the gene expression level based on experimental
data from CMap. We identified the most connected genes in
this network and evaluated whether this high-degree connectivity was exclusively associated with NIDs. We provide
literature-based evidence of the effects that perturbation of
these genes has in the neurological setting. We propose this
approach as a method to identify genes and associated biological functions that have not been previously used for the
study of DIPN.
METHODS
Peripheral NIDs
We used 234 drugs from a previous study of DIPN10 in which
a text-mining approach was used to identify a list of drugs
associated with DIPN by using information from drug labels
retrieved from the Drugs@FDA database.19 In addition, this
information was complemented using DailyMed20 and the
Side Effect Resource.21
CMap
The CMap12,13 is an important resource for the study of
pharmacological effects on gene expression. It contains
data from a series of perturbation experiments on a variety
of cell lines spanning a variety of experimental conditions.
A major asset of this resource is the fact that comparability among samples is achieved by virtue of the experimental design, which aims to reduce batch effects and other
artifacts. For our work, we retrieved the CMap transcriptional profiles currently available, which contain expression
profiles for 6,100 different experimental conditions. These
profiles were analyzed in the Affymetrix Human Genome
U133A platform (Affymetrix, Santa Clara, California).
In CMap, each treatment is described by a nonparametric
rank-ordered list of all probe sets in the microarray platform.
The expression level of each probe after treatment is compared with the expression of the same probe in a vehicle
control sample, and the differences between these expression levels are ranked with the highest ranked probe representing the probe exhibiting the maximum up-regulation
(or activation) after treatment and the lowest ranked probe
exhibiting the maximum down-regulation (or inhibition) after
treatment.
Generation of unique drug sample profiles
The CMap data include transcriptomic profiles for 98 of the
234 NIDs listed in our previous work.10 Two of these NIDs
CPT: Pharmacometrics & Systems Pharmacology

(exemestane and topiramate) had only one profile corresponding to one experimental condition tested, whereas the
remaining 96 were profiled in more than one experimental
condition (see Table S1). To have a representative ranked
expression profile for each drug, we followed the Kruskal–
Borda strategy described by Iorio et al.22 For all the rank-
ordered lists originating from the same drug, a distance
metric was computed (in this implementation, Spearman’s
Footrule is used). The two closest samples were merged
through a majority voting system and reranked until a single
consensus profile for the drug was obtained. The result was
a ranked expression matrix in which each column contains
a drug, and each row contains the rank of the transcript’s
expression level. Transcripts belonging to the same genes
were aggregated to the gene level using the maximum expression level among them.
Drug–gene perturbation network
To model the relationships between NIDs and genes experimentally found in the CMap, we employed a network-based
approach. A network is a mathematical object composed
of a set of nodes and a set of edges or links representing
relationships between these nodes. In the case of a biological network, for instance, nodes can represent molecules,
whereas edges can represent the physical and chemical
interactions between them. In this work, we modeled the effects of the drug on gene expression as a bipartite network,
which is composed of the following two classes of nodes:
drugs and genes. Edges connect drugs and genes, representing an action of drug treatment on gene expression.
The network space was populated with the nodes of two
types, representing the 98 NIDs whose perturbation profiles
were included in CMap and the 12,438 genes measured in
the microarray platform. An edge in the network was drawn
between a drug and a gene if the gene was ranked in the
top 100 positions (up-regulation) or the bottom 100 positions (down-regulation). This criterion was decided because
the available data consist of ranked gene lists for each drug,
which do not allow, for instance, to select any number of
genes above a certain threshold (e.g., a significance threshold for differential expression values). The changes in gene
expression induced by drugs can be generally thought of
as markers of gene susceptibility to drug perturbation. The
network model is then a representation of the potential susceptibility of a given gene to be affected by different drugs.
Construction of null models
To assess the significance of network properties, the generation of comparable networks through a null model is
necessary. This should reflect the nature of the phenomenon being modeled through the biological network to be
useful.23 Two main questions arise when analyzing the of
NID perturbation network generated in this work: (i) whether
the NID perturbation network structure is different from a
randomly generated network and (ii) whether the network
properties, particularly the degree, of a particular gene in
the NID perturbation network can be associated exclusively
to NIDs and not to other non-neuropathy–inducing drugs.
To answer these questions, we generated networks using
two different null models.
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The first null model consists of generating 98 artificial
drug profiles with rank values randomly assigned to all
12,438 genes. The top 100 and the bottom 100 ranked
genes were selected to draw a link between the drugs
and genes. This is equivalent to a random rewiring, preserving the degree distribution of the drug layer nodes.
We refer to this model as the randomly generated null
model. We use this model to assess whether the network
topology of the pharmacologically relevant network is different from that expected by randomly connecting drugs
and genes.
The second null model evaluates whether the topological properties, such as degree, of a given node are exclusive to the neuropathy-related network. In this model,
98 drugs were randomly selected from the complete list
of drugs included in the CMap data set (n = 1,211), excluding the 98 NIDs. Then, the top 100 and bottom 100
ranked genes for each profile are connected to the drug
nodes. We refer to this model as the randomly selected
drug model. With each model, an ensemble of 5,000 networks was generated.
Degree as a measure of relative importance of genes
in the neuropathy context
Genes that are affected by a larger number of NIDs may
be more related to the underlying mechanisms driving the
pathological phenotype associated with these drugs. A fundamental network-based metric that can be used to identify such genes is their degree—the number of neighbors
in the graph, which in our model represents the number of
drugs that can affect that gene.
The distribution of degree values is one of the most
defining properties of any given network and can be used
to categorize the nature of a particular network as well as
for comparison purposes.24 To test the pharmacological
significance of the drug perturbation network, the degree distribution of our experimental network was compared with those of the randomly generated null model
networks using the Kolmogorov–Smirnov and χ2 tests. In
addition, Hellinger distance and Jensen Shannon divergence were computed.
The genes were selected based on their higher degree
in the NID network, considering that genes that were connected to 10 or more drugs (10% of the total evaluated
drugs) were more likely to be related to the neuropathic condition. The rationale behind this selection cut-off was that
randomly generated networks such as the ones from the first
null model did not have nodes with a degree higher than 10.
To further refine this selection, a secondary filtering was
used, specifically whether a gene, identified as susceptible to NIDs by having a high degree, is more susceptible
to these drugs than to other drugs that are not known to
induce peripheral neuropathy. For each gene, an empirical
distribution of degree frequency was constructed from the
randomly selected drug networks. The degrees of the highly
connected genes (degree ≥ 10) in the NID perturbation network were compared against these empirical distributions
by calculating a Z-score. Those genes with a Z-score equal
to or above 1.96 (equivalent to P value < 0.05) were considered to have a high degree in the neuropathy context.

Function identification and literature-based validation
We explored the National Center for Biotechnology
Information (NCBI) gene database25 to identify the functions in which the identified genes are generally involved.
We used this information to generate a list of functions that,
through associations to these genes, may be involved in the
development of DIPN. In addition, we looked for the identified genes in a list of known housekeeping genes.26 We
queried PubMed abstracts using SciMiner,27 a web-based
literature-mining tool, to find papers where these functions
are reported in a neurological context. The queries took the
form of function AND nerve, function AND neuron, or function AND pain, for instance, “transcription AND neuron.”
RESULTS
Network parameters
As illustrated in Figure 1, a network of 98 NIDs, of the original 234 drugs reported in our previous work,10 and their
perturbed genes was generated based on gene expression
perturbation profiled in CMap. The CMap drug perturbation
profile data contained a set of 12,438 genes; however, 5,300
of these genes were not connected (either through up-or
down-regulation in the context of the CMap perturbation
experiments) to any of the NIDs. The remaining 7,138 genes
were perturbed by at least one drug and therefore were included in the network, having a degree of one or higher. Of
these connected genes, 2,556 (35.81%) genes were connected exclusively to a single NID. The parameters of this
network are summarized in Table 1, and Supplementary
Material S1 contains the complete network in gml format,
which can be visualized with Cytoscape 3.28
One of the fundamental network measures is the cumulative
degree distribution, which describes the cumulative frequency
of degree values in the network. Figure 2 illustrates the degree
distribution (in terms of 1 − the cumulative distribution function) of gene nodes in the network as well as the distributions
for comparable networks generated through the null model. The
experimental distribution, represented by the solid line, was different (average Benjamini–Hochberg BH-
corrected P values
for Kolmogorov–Smirnov = 3.4 × 10−6, χ2 = 1.2 × 10−6; average
Hellinger distance = 0.1026, average Jensen Shannon divergence = 0.0105) from those of the randomly generated null model
networks, whose average is represented by the dotted line.
We define the unique neighborhood of a node as the set
of neighbors of a node that are not shared by any other node
in the network. It is a measure of the overlap between genes
targeted by each drug. Figure 3 illustrates the different distributions of unique neighborhood sizes for drug nodes in
the NID network (represented with the black, shaded distribution) in the randomly generated null model networks (represented with multiple colored distributions to the right) and
for the randomly selected drug networks (multiple colored
distributions to the left). The displacement of the distribution
to the left indicates that, on average, the drugs are affecting
genes unaffected by any other drug in the network.
The largest connected component of a network is the
subgraph that contains the most connected nodes in a network. The size of this component can be used as a simple
measure of network cohesiveness. Figure 4 shows the size
of the largest connected component of the network for the
www.psp-journal.com
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Figure 1 Drug–gene perturbation network visualization. Drugs are arranged in a circle (blue nodes), linked to genes through either
upregulation (red links) or downregulation (green links). Genes perturbed by a single drug are oriented outside, whereas genes
perturbed by multiple drugs are oriented inside the drug node circle. Transparency and sizes of nodes and edges were adjusted
(based on degree and edge betweenness) for visualization purposes.

NID network compared with the size distribution of the randomly generated networks and the randomly selected drug
networks. It is shown that the size of the largest connected
component of the NID network is significantly smaller than
that of the randomly generated networks and larger than
that of the randomly selected drug networks.
Genes with high degrees and their functional
relevance
In this work, highly connected genes are considered more
likely to be involved in the neuropathic condition. We
CPT: Pharmacometrics & Systems Pharmacology

defined these highly connected genes as those with a degree of 10 or higher; 64 such genes were identified, which
can be found in Table S2. Of these genes, 27 were found
with a degree value significantly higher (Z-score ≥ 1.96)
than that expected from the ensemble of networks derived
from randomly selected drug networks. These genes and
their biological functions can be found in Table 2 .
Based on the functions identified for this list of genes,
a systematic literature revision was performed. Figure 5
shows the results of the SciMiner queries to identify the
biological functions whose perturbations we propose to be
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Table 1 Drug–gene perturbation network parameters
Values

Parameter
Drugs

98

Genes

12,438

Connected genes

7,138

Edges

19,600

Maximum degree (connected genes)

15

Number of connected components

1

associated with DIPN in neurological or pain-related contexts. Figure 5a shows the number of papers identified by
these queries. Figure 5b shows the number of genes whose
perturbations are associated with these queries. Finally,
Figure 5c shows the number of papers in which genes identified in our NID network are found in the context of these
queries (see Table S3 for the list of PubMed identifiers for
each gene–query pair).
DISCUSSION
In this work, data from high-
throughput 
perturbation
xperiments of NIDs were integrated into a 
e
bipartite
network model of drugs and perturbed genes. We

observed that this network has a unique topology, with
a degree distribution distinct from comparable random
bipartite networks. The neighborhood of each drug node
was unique and in each case was defined by a set of genes
that are only perturbed by this drug and no other. None
of the highly perturbed genes were connected to more
than 15% of the NIDs, which suggests the involvement of
diverse mechanisms leading to DIPN. These mechanisms
may be associated with the alteration of biological functions in which the most connected genes in this network
are involved. Therefore, we identified these highly connected genes in the NID network and demonstrated that

their degree was high exclusively in the context of NIDs.
Through systematic queries of the current biomedical
literature using a text-mining approach, we identified instances in which perturbations of these genes have been
reported in neurological or pain-related settings, some of
which are discussed below.
The topology of the NID network was completely different
from those of the randomly generated null model networks
with respect to the degree distribution of gene nodes, overlap in gene neighbors of drug nodes, and size of the largest connected components. The degree distribution of drug
nodes was constant because the network was constructed
using the same number (100) of genes for each drug; however, the degree distribution of gene nodes was variable
from 1 to 15. The degree distribution of the NID network reflects a higher quantity of disconnected gene nodes (that is,
with degree 0) compared with the null model (see Figure 2).
It also shows that in the NID network, there are genes with a
degree value higher than the highest found in the null model.
The overlap in the gene neighbors of drug nodes was
also different between the NID network and the randomly
generated networks. This finding suggests that the genes
affected by NIDs are not randomly distributed throughout
the genome but, rather, certain genes are preferentially affected by these drugs. However, our results indicate that this
preference is not exclusive to NIDs, as the networks generated from randomly selected non-NIDs also had smaller
unique neighborhoods when compared with the randomly
generated networks.
All drug nodes in the NID network, as well as the networks generated from the null models, are part of a single
connected component, that is, a path can be traced from
any drug to any other drug. The sizes of the largest connected component were significantly different between the
NID network and those from both null models. The randomly
generated networks had larger connected components than
either the NID network or randomly selected drug networks.

0.75

0.75

P(K)

(b) 1.00

P(K)

(a) 1.00
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Figure 2 Degree frequency distribution. (a) The values for 1−(degree cumulative distribution function) (P(K)) vs. degree (K) for the
neuropathy-inducing drug–gene perturbation network as a thick black line is illustrated. (b) The average value of P(K) vs. K is shown
as a dotted line for the networks in the randomly generated null model ensemble (5,000 networks). For each value of K, error bars are
shown indicating the 5th and 95th percentile regions of values observed in the randomly generated null model ensemble networks.
The major difference between the two panels is that the distributions for the random networks (b) have a maximum degree value of 10,
whereas the drug-induced peripheral neuropathy network (a) has a maximum degree value of 15.
www.psp-journal.com
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Table 2 High-d egree genes, neuropathy-s pecificity Z-score, and biological role
Entrez gene ID

Symbol

Description

Degree

Z-score

Involved ina

54820

NDE1

nudE neurodevelopment
protein 1

15

1.93

Microtubule organization

5971

RELB

RELB proto-oncogene,
NF-kB subunit

14

2.16

Transcription factor

25819

NOCT

Nocturnin

14

4.06

Circadian regulation

64319

FBRS

Fibrosin

14

2.61

Fibroblast proliferation

2152

F3

Coagulation factor III, tissue
factor

12

2.18

Coagulation

5296

PIK3R2

Phosphoinositide-3 -kinase
regulatory subunit 2

12

2.54

Signal transduction

28990

ASTE1

Asteroid homolog 1

12

3.9

Uncharacterized

51564

HDAC7

Histone deacetylase 7

12

2.51

Histone modification

57827

C6orf47

Chromosome 6 open reading
frame 47b

12

2.28

Uncharacterized

1179

CLCA1

Chloride channel accessory
1

11

3.21

Ion channel

1271

CNTFR

Ciliary neurotrophic factor
receptor

11

3.15

Neurite outgrowth

2356

FPGS

Folylpolyglutamate synthaseb

11

2.16

Folate metabolism

9816

URB2

URB2 ribosome biogenesis 2
homolog (S. cerevisiae)

11

2.08

Uncharacterized

27156

RSPH14

Radial spoke head 14
homolog

11

2.28

Microtubule organization

51224

TCEB3B

Elongin A2

11

3.29

Transcription elongation

54332

GDAP1

Ganglioside induced
differentiation associated
protein 1

11

2.1

56672

AKIP1

A-kinase interacting protein 1

11

3.58

2161

F12

Coagulation factor XII

10

3.53

Coagulation

3783

KCNN4

Potassium calcium-activated
channel subfamily N
member 4

10

2.52

Ion channel

4998

ORC1

Origin recognition complex
subunit 1

10

2.99

Cell cycle control

5393

EXOSC9

Exosome component 9

10

2.2

RNA degradation

5565

PRKAB2

Protein kinase AMP-activated
noncatalytic subunit beta 2

10

2.15

Signal transduction

9827

RGP1

RGP1 homolog, RAB6A GEF
complex partner 1b

10

3.37

Signal transduction

22994

CEP131

Centrosomal protein 131

10

2.71

Microtubule organization

26468

LHX6

LIM homeobox 6

10

3.9

Transcriptional regulation

54714

CNGB3

Cyclic nucleotide gated
channel beta 3

10

2.74

Ion channel

79157

MFSD11

Major facilitator superfamily
domain containing 11b

10

1.95

Solute carrier (49Perland et
al., 2016)

a

Mitochondrial metabolism

Signal transduction

Based on annotation from the NCBI gene database25 unless otherwise noted. bHousekeeping gene according to Eisenberg and Levanon. 26

This finding is consistent with what has been previously discussed regarding the preferential targeting of certain genes
by drugs; experimentally, the drugs were found to act in a
subset of the genome, leaving untargeted genes disconnected in the network. Between the NID and the randomly
selected drug networks, the NID network’s largest component was significantly larger. This result shows a difference
in the topology of the NID network when compared with the
networks of non-NIDs.
Although the NID network included more genes with a
higher degree than the randomly generated networks (64
genes with a degree of 10 or higher), no single gene was
CPT: Pharmacometrics & Systems Pharmacology

connected to all NIDs. Therefore, we propose that DIPN
may not be explained by the perturbation of a single gene
(and associated biological function) but, rather, that each
NID may have effects on different biological functions (thus
altering the expression of the associated genes), which collectively lead to the neuropathic condition. We focused on
the group of genes that, based on the higher degree in the
NID network, were susceptible to the effects of more neuropathic drugs. Those genes with a high degree exclusively
associated to NIDs (Table 2) serve as proxies to the biological functions that are perturbed by NIDs. The evidence
of these genes’ perturbation in neurological contexts was

Network Pharmacology of Neuropathy-Inducing Drugs
Anda-Jáuregui et al.
217

Figure 3 Unique neighborhood size distribution. The unique
neighborhood size distribution for drug nodes in the drug-
induced peripheral neuropathy network and the null models
are shown. Distributions for the randomly generated networks
are seen to the right, centered in a size 40. Distributions for
the randomly selected drug networks are seen to the left, with
a mode near size 20. The distribution for the drug-
induced
peripheral neuropathy network is shown in black shading; it
should be noted that because this distribution lies completely
in the region of randomly selected drug networks, it is indicated
that the drug-
induced peripheral neuropathy network differs
in terms of neighborhood size distribution from the randomly
generated networks but not from the randomly selected drug
networks.

collected using literature mining (Figure 5), which gives credence to the idea of these genes being potentially involved
in the neuropathy.
Some of the genes identified using the NID network have
strong associations to a neuropathic mechanism. For instance, impaired function of neuronal mitochondria has
been proposed as having an important role in the development of neuropathies.29 One of the genes identified in this
work is ganglioside-induced differentiation-associated protein 1 (GDAP1), a gene that encodes an outer mitochondrial
membrane protein. It acts as a regulator of mitochondrial
fission,30 and there is abundant evidence associating alterations of this gene to the hereditary Charcot-Marie-Tooth
neuropathy (CMT). Different mutations of this gene have
been observed and linked to different clinical manifestations
of CMT.31,32 Some mechanisms involving changes in mitochondrial movement, abnormal distribution,33 and perturbations in mitochondrial fission34 in CMT have been associated
with mutations of GDAP1. Our results may provide a starting
point for further exploration of therapies targeting mitochondrial processes,35 which might have beneficial effects in the
treatment of DIPN.
Another example is potassium intermediate/small conductance calcium-activated channel, subfamily N, member
4 (KCNN4), encoding an intracellular calcium-activated potassium channel. KCNN4 is expressed in the nervous system with distinctive expression patterns across cellular and
subcellular regions.36 This channel has just recently been
targeted and shown to reverse tactile allodynia in a model of
peripheral nerve injury in rodents.37
The exploration of the NID network allows the identification of such genes, which have been identified in other

Figure 4 Largest connected component size distribution. The
largest connected component size distribution is shown for the
null models. The distribution for the randomly generated network
model is shown to the right in yellow (mean value = 9,898). The
distribution for the randomly selected drug network model is
shown to the left in blue (mean value = 67,367). A dotted line
indicates the largest connected component size for the drug-
induced peripheral neuropathy network, consisting of 7,236
nodes.

neuropathic settings, but it also points to those less explored. For instance, nudE nuclear distribution gene E
homolog 1 (NDE1) is a gene involved in microtubule organization and encoding a protein that is part of the dynein complex. Although there is no evidence directly linking NDE1 to
neuropathies, other elements of the dynein complex have
been found to malfunction in cases where defects in axonal
transport lead to CMT.38,39 Ciliary neurotrophic factor receptor (CNTFR) is another gene identified in the NID network
that has not been associated with neuropathies. However, it
is involved in neuronal survival,40 and the signaling pathways
activated through these receptors lead to protective effects
against neurotoxicity in dopaminergic cells.41
Some of the genes identified through the network analysis have been barely explored. We would like to call special
attention to nocturnin (NOCT), a gene involved in circadian
regulation. The network model identifies it as one of the
most connected (affected by 14 drugs) and, most important, one of the most exclusively associated only to NIDs.
Although we found no information in the literature related to
a role of these genes in a neurological (let alone neuropathic)
setting, we believe, based on the network model, that further
experimental exploration of these genes may provide insight
on neuropathies.
When interpreting the significance of these highly connected genes in networks derived from transcriptional
information such as ours, one important consideration
is that housekeeping genes, playing functionally central
roles, may also be topologically central.42 We compared
our highly connected genes with a curated list of housekeeping genes26 and identified 12 such housekeeping
genes among the 64 highly connected genes, which suggest no significant enrichment (P value = 0.2 by hypergeometric test). Among the 27 significant highly connected
genes, there were only four housekeeping genes (Table 2).
It is plausible to think that in the case of these genes, their
www.psp-journal.com
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Figure 5 Heatmaps of literature-based validation: (a) the number of genes associated to a particular query (combination of keywords),
(b) the number of papers indexed in PubMed, identified using PubMed IDs (PMID), retrieved by a combination of keywords, (c) the
number of papers in which a given gene is associated to a particular query.

perturbation by NIDs affects the functionality of the cell;
the mechanism through which this perturbation may induce the neuropathic condition remains to be described.
There are certain limitations to our model, mostly imposed
by the availability of high-throughput experimental data. The
coverage of NIDs in the CMap is limited and only 98 of 234
NIDs were included in the present study. The high-throughput
profiles available in CMap were generated using gene perturbation experiments in cancer cell lines (MCF7 Michigan
Cancer Foundation-7, ssMCF7 ss = serum starved, HL60
Human Leukemia, PC3 Prostate Cancer, and SKMEL5 Skin
Melanoma). The responses observed in these cell lines may
not completely reflect the activity of a drug in vivo and in the
context of drug-induced neuropathy. These cell lines were
not derived from nerve or brain tissues. Although the CMap
data may not reflect the specificity in neuronal tissues, they
are still useful in understanding overall drug-perturbed transcriptional responses and have been used for other nervous
system conditions43–45 as well as for adverse drug reaction
studies.16,46
The available perturbation profiles are provided as
ranked gene lists, which forbids the use of individual selection criteria to identify the neighborhood of genes that
are significantly perturbed by each drug. This consideration, along with the representativity of CMap data of the
neurological context, was behind the decision of modeling
only gene perturbation in the current study as opposed to
using gene up/down regulation. If these limitations could
be resolved, it would be possible to further discuss the
contributions of these gene perturbations in terms of loss
and gain of functions, which would further lead to the potential use of drugs inducing opposite perturbations in a
drug-repurposing setting.
However, as more high-throughput data sets are released,
the model may be refined and updated. The CMap itself
has been expanded and integrated to the larger Library of
CPT: Pharmacometrics & Systems Pharmacology

Integrated Network-
Based Cellular Signatures,47 which will
increase the coverage of drugs evaluated and provide perturbation profiles in cell lines more representative of the tissues
of interest. Furthermore, the integration of other data sources
beyond gene perturbation profiles into network models may
allow for deeper and more meaningful interpretation of the role
of genes in pathological conditions. The sources of this information vary, as they may come from general drug resources or
information related to the specific subject such as the different
forms of peripheral neuropathy used in our study. However,
integrating the information of these resources to generate
network models may not be trivial, even if the available information may be already represented as a network, and the differences in construction methods would make the networks
incomparable unless adaptations are made.
The study of pharmacology from a systems perspective
and the use of networks for this purpose are quickly becoming the norm. Network models are needed to understand
the on and off-target effects of drugs that are involved in
their therapeutic and adverse effects.48 The work presented
in this article is an example of an application of network
models that may provide new insights into the nature of
DIPN.
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